A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17–20th December). The communication was given by Dr Alex Conibear who is working in Prof Eamonn Kelly’s research group at the University of Bristol funded by a Medical Research Council project grant to PharmNovo and Prof Kelly for the study of biased signalling via delta opioid receptors. The potential clinical use of PN6047 for the treatment of chronic pain and, in particular, mechanical allodynia, was explained and a detailed account of its biased signalling profile was given.
JPET approves PN6047
In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
Read more →Moving into The Spark
In September PharmNovo AB officially moved to Medicon Village in Lund and the newly opened building ”The Spark”. Being located at Medicon Village offers great opportunities for networking and finding new collaboration and service partners. Being one of the largest life science hubs in the Nordics, Medicon is also a fantastic platform for marketing our company and attracting future investors and partners.
Read more →Christmas BPS
A paper entitled “PN6047, a G protein-biased delta opioid receptor agonist with an improved therapeutic profile for use in chronic pain” was delivered at the Christmas meeting of the British Pharmacological Society at London’s QE2 Centre (17–20th December). The communication was given by Dr Alex Conibear who is working in Prof Eamonn Kelly’s research group at the University of Bristol funded by a Medical Research Council project grant to PharmNovo and Prof Kelly for the study of biased signalling via delta opioid receptors. The potential clinical use of PN6047 for the treatment of chronic pain and, in particular, mechanical allodynia, was explained and a detailed account of its biased signalling profile was given.
Read more →A key step
PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. The European Patent Office is very likely to follow suit early in 2019. PN6047 is a biased delta opioid receptor agonist (DOBRA) favouring signalling through G proteins and, in preclinical testing, it has none of the unwanted side effects of conventional opioid analgesics. PharmNovo AB have been granted a patent in the USA for our candidate delta opioid receptor agonist PN6047. This is a key step towards clinical testing for the treatment of chronic pain states.
Read more →
